<i>Notes from the Field</i>: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus — Five States, October 2023–February 2024

The antiviral drug tecovirimat* has been used extensively to treat U.S. mpox cases since the start of a global outbreak in 2022. Mutations in the mpox viral protein target (F13 or VP37) that occur during treatment can result in resistance to tecovirimat<sup>†</sup> (1,2). CDC and public health partners have conducted genetic surveillance of monkeypox virus (MPXV) for F13 mutations through sequencing and monitoring of public databases. MPXV F13 mutations associated with resistance have been reported since 2022, typically among severely immunocompromised mpox patients who required prolonged courses of tecovirimat (3-5). A majority of patients with infections caused by MPXV with resistant mutations had a history of tecovirimat treatment; however, spread of tecovirimat-resistant MPXV was reported in California during late 2022 to early 2023 among persons with no previous tecovirimat treatment (3). This report describes a second, unrelated cluster of tecovirimat-resistant MPXV among 18 persons with no previous history of tecovirimat treatment in multiple states.

Authors

Publication Details

Journal
MMWR Morbidity and Mortality Weekly Report
Published
2024-10-10
DOI
https://doi.org/10.15585/mmwr.mm7340a3
Citations
21
Primary Topic
Poxvirus research and outbreaks
Type
article
Field-Weighted Citation Impact
6.17

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus — Five States, October 2023–February 2024

Kirstin Short, C. Kling, Julie Hand, Hannah J. Barbian et al.
21 citations
MMWR Morbidity and Mortality Weekly Report
Poxvirus research and outbreaks
6.17
article

Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus — Five States, October 2023–February 2024

Kirstin Short, C. Kling, Julie Hand, Hannah J. Barbian, Monica Haw, Gillian Richardson, Agam K. Rao, Jill K. Hacker, Kimberly S. Johnson, Meilan Bielby, Kimberly Wilkins, Nicolle Baird, Christina L. Hutson, Danielle Haydel, Chantha Kath, Alex Espinosa, Thomas A. Smith, Emma Ortega, Jacob M. Garrigues, Alyse Kittner, Nicole Green, Whitni Davidson, Christine Hughes, Taylor Holly, D McGrath, Jade Takakuwa, Crystal M. Gigante, Nelson De La Cruz, Mengfei Peng
article en
21 citations

Abstract

The antiviral drug tecovirimat* has been used extensively to treat U.S. mpox cases since the start of a global outbreak in 2022. Mutations in the mpox viral protein target (F13 or VP37) that occur during treatment can result in resistance to tecovirimat<sup>†</sup> (1,2). CDC and public health partners have conducted genetic surveillance of monkeypox virus (MPXV) for F13 mutations through sequencing and monitoring of public databases. MPXV F13 mutations associated with resistance have been reported since 2022, typically among severely immunocompromised mpox patients who required prolonged courses of tecovirimat (3-5). A majority of patients with infections caused by MPXV with resistant mutations had a history of tecovirimat treatment; however, spread of tecovirimat-resistant MPXV was reported in California during late 2022 to early 2023 among persons with no previous tecovirimat treatment (3). This report describes a second, unrelated cluster of tecovirimat-resistant MPXV among 18 persons with no previous history of tecovirimat treatment in multiple states.

MMWR Morbidity and Mortality Weekly ReportVol. 73(40)
Association of Public Health Laboratories, Centers for Disease Control and Prevention, Oak Ridge Institute for Science and Education
Zero hunger
Openalex Percentile: Top 3%
Poxvirus research and outbreaks
6.17
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.